Anti pd 1 clone rmp1 14

Manufactured by BioXCell

Sourced in United States

Anti-PD-1 (clone RMP1-14) is a monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor. It is commonly used as a research tool in cell biology and immunology studies.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

RMP1-14 (124 citations) Anti-PD-1 (65 citations) Clone RMP1-14 (36 citations) Anti-PD-1 antibody (clone RMP1-14, (17 citations) Anti-mouse PD-1 (clone RMP1–14; (15 citations) Anti-PD-1 mAb (clone RMP1-14; (8 citations) Anti-mouse PD-1 antibody (clone RMP1-14) (6 citations) Anti-PD-1 antibodies (clone: RMP1-14) (3 citations) Anti-PD-1 Ab (clone RMP1-14, (3 citations) Anti-mouse PD-1 (CD279) (clone RMP1-14) (3 citations)

54 protocols using anti pd 1 clone rmp1 14

Infection Protocols for Influenza, LCMV, Staphylococcus, and Vaccinia Virus

Check if the same lab product or an alternative is used in the 5 most similar protocols

For influenza infections, mice were inoculated (10,000 pfu in 40 μl) with influenza A/H1N1/PR8 or influenza-OVA (A/H1N1/PR8-OVA) via intranasal administration (Rutigliano et al., 2014 (link)). For LCMV infections, mice were inoculated with LCMV Armstrong strain (2×10⁵ pfu) by intraperitoneal (i.p.) injection. For Staphylococcus aureus (strain COL) skin infections, a 5-mm biopsy punch was used to create four full thickness wounds in the dorsal skin of mice, opposite from the ventral site of the tumor (Kroin et al., 2015 (link)). Staphylococcus aureus was applied to the wounds (1×10⁷ cfu in 10 μL PBS). Mice were housed in individual cages after wounding to prevent cross-contamination. For vaccinia virus (VACV) skin infections, B6 mice were inoculated with VACV (NYCBH strain) via intradermal (i.d.) injection (10⁶ PFU) and analyzed by plaque assays (Zhang et al., 2006 (link)). For PD-1 blockade, anti-PD-1 (clone RMP1–14; BioXCell; 250 μg) or matched IgG control antibody was administered via i.p. injection.

Kohlhapp F.J., Huelsmann E.J., Lacek A.T., Schenkel J.M., Lusciks J., Broucek J.R., Goldufsky J.W., Hughes T., Zayas J.P., Dolubizno H., Sowell R.T., Kühner R., Burd S., Kubasiak J.C., Nabatiyan A., Marshall S., Bommareddy P.K., Li S., Newman J.H., Monken C.E., Shafikhani S.H., Marzo A.L., Guevara-Patino J.A., Lasfar A., Thomas P.G., Lattime E.C., Kaufman H.L, & Zloza A. (2016). Non-oncogenic acute viral infections disrupt anti-cancer responses and lead to accelerated cancer-specific host death. Cell reports, 17(4), 957-965.

+ Open protocol

+ Expand

Evaluating Immunotherapeutic Interventions in Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice were injected subcutaneously (s.c) with OVA (0.5 mg/mouse) (day 0) combined with Imiquimod cream (Meda-Aldara™; topical application; 2.5 mg/mouse; days 0-2) or poly(I:C) (Amersham; 50 μg/mouse; s.c.; day 0). When using peptide TRP2(180–188), mice received 50 μg of peptide (s.c.; days 0–2) and topical Imiquimod as above. Additionally, the mice received i.p. injection of anti-IL-10R (clone 1B1.3A; 500 μg), anti-PD-1 (clone RMP1–14; 200 μg) or the corresponding isotype control antibodies (all from BioXcell) the day of immunization, with or without 30 mg/kg of RXDX-106 (oral route) administered from day 0 to 5. In some experiments, C57BL6/J mice were injected i.v. with 5 x 10⁶ CD4 cells obtained from OT-II mice after purification by negative selection (Miltenyi Biotec) and immunized 24 h later. Mice were sacrificed at day 2 for MER, AXL and IL-10 analyses and at day 7 for ELISPOT assays, and splenocytes or tumor-infiltrating cells were obtained for immune characterization.

Llopiz D., Ruiz M., Silva L., Reparaz D., Aparicio B., Egea J., Lasarte J.J., Redin E., Calvo A., Angel M., Berzofsky J.A., Stroncek D, & Sarobe P. (2020). Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy. Cancer letters, 499, 279-289.

+ Open protocol

+ Expand

Pharmacological Inhibition in Cancer Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

For in vivo pharmacological inhibition, gemcitabine (Selleck Chemicals) was dosed at 100mg/kg IP. SX-682 (Syntrix Pharmaceuticals) was dosed PO ad libitum (formulated concentration 714mg/kg feed); therapeutic plasma levels (range 0.5–10 μg/mL) were confirmed with this feed using LC/MS-MS. For ICT and Gr1/CD8-neutralizing antibody treatment, anti-PD1 (clone RMP1–14, BioXCell, BE0146), anti-CTLA4 (clone 9H10, BioXCell, BE0131), anti-TIM3 (clone RMT3–23, BioXCell, BE0115), anti-OX40 (clone OX-86, BioXCell, BE0031), anti-41BB (clone LOB12.3, BioXCell, BE0169), anti-LAG3 (clone C9B7W, BioXCell, BE0174), anti-CD8 (clone 2.43, BioXCell, BE0061) and anti-Gr1 (clone RB6–8C5, BioXCell, BE0075), antibodies (or their respective isotype IgG controls) were intraperitoneally administered at 200μg per injection three times per week. The duration of treatment was 4 weeks before endpoint analysis and survival analysis unless otherwise indicated.

Gulhati P., Schalck A., Jiang S., Shang X., Wu C.J., Hou P., Ruiz S.H., Soto L.S., Parra E., Ying H., Han J., Dey P., Li J., Deng P., Sei E., Maeda D.Y., Zebala J.A., Spring D.J., Kim M., Wang H., Maitra A., Moore D., Clise-Dwyer K., Wang Y.A., Navin N.E, & DePinho R.A. (2022). Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/2 results in anti-tumor immunity and durable response in pancreatic cancer. Nature cancer, 4(1), 62-80.

+ Open protocol

+ Expand

Monoclonal Antibody Depletion in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Monoclonal antibodies were delivered to mice by IP injection (200 μg/mouse in 200 μl of PBS). For depletion experiments, anti-CD8α antibodies (clone 2.43) were purchased from Bio X Cell (West Lebanon, NH). Anti-PD-1 (clone RMP1–14) was purchased from Bio X Cell (West Lebanon, NH). Delivery schedules are detailed in Additional file 1: Supplemental Methods. Flow cytometry antibodies were purchased from BD Biosciences (San Jose, CA), eBiosciences (Thermo Fisher Scientific, Waltham, MA), or BioLegend (San Diego, CA) and clones/staining procedures are detailed in Additional file 1: Supplemental Methods.

McGray A.J., Huang R.Y., Battaglia S., Eppolito C., Miliotto A., Stephenson K.B., Lugade A.A., Webster G., Lichty B.D., Seshadri M., Kozbor D, & Odunsi K. (2019). Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. Journal for Immunotherapy of Cancer, 7, 189.

+ Open protocol

+ Expand

Spontaneous Regression Mouse Model

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The YUMMER1.7 spontaneous regression mouse model was described previously (Wang et al., 2017 (link)). Briefly, C57BL/6J mice (4 – 6 weeks old) were implanted subcutaneously in the rear flank with 100 μl of syngeneic YUMMER1.7 cells in PBS. Immunotherapy (anti-CTLA-4 (clone 9H10, Bio X Cell, West, Lebanon, NH, USA), anti-PD-1 (clone RMP1–14, Bio X Cell)), or corresponding isotype controls (Syrian hamster IgG2, Rat IgG2a, respectively) were injected 6 days post cell line implantation at 10 mg/kg three times per week for four weeks. All animal experiment protocols were followed according to the Yale Office of Animal Research Support Committee guidelines.

Blenman K.R., Wang J., Cowper S, & Bosenberg M. (2019). Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma. Pigment cell & melanoma research, 32(3), 448-457.

+ Open protocol

+ Expand

In Vivo Immune Checkpoint Blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies used for in vivo studies were anti-KLRG1 (ABC-m01, Abcuro, Inc.), anti-PD-1 (clone RMP1-14, BioXcell), and control (rat IgG2a, clone 2A3, BioXcell). Antibodies used for flow cytometry were anti-CD8a (clone 53-6.7, PerCP-Cy5.5, Beckton Dickinson) and anti-KLRG1 (clone 2F1, Biolegend).

Greenberg S.A., Kong S.W., Thompson E, & Gulla S.V. (2019). Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. Oncotarget, 10(14), 1399-1406.

+ Open protocol

+ Expand

Glioblastoma Tumor Growth Monitoring and Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

GBM initiation and growth development was monitored by BLI as described above and animals that reached >1X10⁷ p/s/cm²/sr were randomly enrolled in treatment groups. All antibodies were diluted with sterile 0.9% Saline (Hospira). Mice were injected i.p. with 200 μg of anti–PD-1 (clone RMP 1–14, BioXcell) and/or 200 μg anti-CTLA4 (clone 9D9, BioXcell), or the isotype control IgG2a mAb (clone 2A3, BioXcell), every 3 days for one cycle. For the immunodepletion experiments, mice were injected with 200 μg of anti-CD8 (clone 53.6.7, BioXcell) daily for 3 days prior to initiation of immune checkpoint blockade or with 200 μg anti-Ly6G (clone 1A8, BioXcell) one day prior to initiation of immune checkpoint blockade and depletion treatment was continued every 3 days for 3 treatments total. AZD-5069 (MedKoo Biosciences, #206473) was resuspended in Ora-Plus (Paddock) and administered daily by oral gavage at a dose of 100 mg/kg body weight for 12 days.

Rijkers G.T., Griffioen A.W., Zegers B.J, & Cambier J.C. (1990). Ligation of membrane immunoglobulin leads to inactivation of the signal-transducing ability of membrane immunoglobulin, CD19, CD21, and B-cell gp95.. Proceedings of the National Academy of Sciences of the United States of America, 87(22), 8766-8770.

+ Open protocol

+ Expand

Immunotherapy Modulating Tumor Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mice received 100 µg of the monoclonal antibody anti-ɣδ TcR (clone UC7-13D5, Bio X Cell) or anti-PD-1 (clone RMP1-14, Bio X Cell) intraperitoneally, in PBS. Anti-ɣδ TcR antibodies were injected the day before tumor implantation and then every 2 days until the end of the experiment. Anti-PD-1 immunotherapy was administered on days 4, 7, and 10 after tumor implantation.

Boucher E., Plazy C., Richard M.L., Suau A., Mangin I., Cornet M., Aldebert D., Toussaint B, & Hannani D. (2023). Inulin prebiotic reinforces host cancer immunosurveillance via ɣδ T cell activation. Frontiers in Immunology, 14, 1104224.

+ Open protocol

+ Expand

Formulating Immunotherapeutic Nanoparticles

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dipalmitoyl phosphatidylcholine (DPPC), phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG-2000), and cholesterol (CHOL) were obtained from A.V.T. Pharmaceutical Co., Ltd. Company (Shanghai, China). ICG, Non-ionic surfactant Triton X-100 (TX-100), and Cell Counting Kit-8 (CCK-8) were obtained from Sigma-Aldrich. Anti-PD-1 (clone: RMP1-14) and anti-TIM-3 (clone: RMT3-23) used in vivo were obtained from Bioxcell. Antibodies against cell surface markers for flow cytometry assay were purchased from Miltenyi and Biolegend. Fetal bovine serum (FBS), DMEM, and RPMI-1640 medium were both obtained from GIBCO Life Technologies Co. Ltd., (USA).

Huang T.Y., Huang G.L., Zhang C.Y., Zhuang B.W., Liu B.X., Su L.Y., Ye J.Y., Xu M., Kuang M, & Xie X.Y. (2020). Supramolecular Photothermal Nanomedicine Mediated Distant Tumor Inhibition via PD-1 and TIM-3 Blockage. Frontiers in Chemistry, 8, 1.

+ Open protocol

+ Expand

Combinatorial Immune Checkpoint Blockade

Check if the same lab product or an alternative is used in the 5 most similar protocols

C57BL/6J mice were s.c. injected in their flank with 0.5 × 10⁶ RET cells. Tumor size was routinely monitored every 3 days using a caliper. When tumors reached 28–30 mm² in size, tumor-bearing mice were randomized to receive a cICB — i.e., neutralizing mAbs anti–PD-1 (clone RMP1-14, 250 μg/mouse) and anti–CTLA-4 (9D9, 100 μg/mouse; Bio X Cell). Mice were injected i.p. with cICBs or combined isotype control antibodies (clone 2A3 and MPC11) 3 times at 3-day intervals. All mAbs and the recommended isotype control mAbs for in vivo use were obtained from BioXcell.

Ferrere G., Tidjani Alou M., Liu P., Goubet A.G., Fidelle M., Kepp O., Durand S., Iebba V., Fluckiger A., Daillère R., Thelemaque C., Grajeda-Iglesias C., Alves Costa Silva C., Aprahamian F., Lefevre D., Zhao L., Ryffel B., Colomba E., Arnedos M., Drubay D., Rauber C., Raoult D., Asnicar F., Spector T., Segata N., Derosa L., Kroemer G, & Zitvogel L. (2021). Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight, 6(2), e145207.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!